Corpus ID: 41559885

Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation.

  title={Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation.},
  author={Yasuko Takahashi and I. Hayashi and Yusuke Tominari and K. Rikimaru and Y. Morohashi and T. Kan and H. Natsugari and T. Fukuyama and T. Tomita and T. Iwatsubo},
  journal={The Journal of biological chemistry},
  volume={278 20},
Nonsteroidal anti-inflammatory drugs (NSAIDs) have been known to reduce risk for Alzheimer's disease. In addition to the anti-inflammatory effects of NSAIDs to block cylooxygenase, it has been shown recently that a subset of NSAIDs selectively inhibits the secretion of highly amyloidogenic Abeta42 from cultured cells, although the molecular target(s) of NSAIDs in reducing the activity of gamma-secretase for Abeta42 generation (gamma(42)-secretase) still remain unknown. Here we show that… Expand
γ-Secretase Modulation with Aβ42-Lowering Nonsteroidal Anti-Inflammatory Drugs and Derived Compounds
The amyloid-β (Aβ) peptides and specifically the highly amyloidogenic isoform Aβ42 appear to be key agents in the pathogenesis of familial and sporadic forms of Alzheimer’s disease (AD). The finalExpand
Effects of sulindac sulfide on the membrane architecture and the activity of γ-secretase
It is suggested that sulindac sulfide directly alters the membrane architecture and shifts the gamma-secretase-mediated cleavage of APP towards a hydrophobic environment where the enzyme-substrate complex is in a conformation for processing preferentially shorter amyloid-beta peptides. Expand
Presenilin Is the Molecular Target of Acidic γ-Secretase Modulators in Living Cells
It is demonstrated that potent acidic GSMs target presenilin to modulate the enzymatic activity of the γ-secretase complex, which is a principal therapeutic target in Alzheimer's disease. Expand
Pharmacological characterization of the novel γ-secretase modulator AS2715348, a potential therapy for Alzheimer's disease, in rodents and nonhuman primates
The promise for AS2715348 is shown as a potential disease-modifying drug for Alzheimer's disease after it was seen to reduce both cell-free and cellular production of Aβ42 without increasing levels of APP β-carboxyl terminal fragment or inhibiting Notch signaling. Expand
Destruxin E Decreases Beta-Amyloid Generation by Reducing Colocalization of Beta-Amyloid-Cleaving Enzyme 1 and Beta-Amyloid Protein Precursor
The data demonstrate that Dx-E represents a novel Aβ-reducing process which could have fewer side effects than secretase inhibitors, and is a natural cyclic hexadepsipeptide which reduces Aβ generation without affecting BACE or PS/γ-secretase activity. Expand
Selective modulation of amyloid‐β peptide degradation by flurbiprofen, fenofibrate, and related compounds regulates Aβ levels
The unexpected conclusion of this work was that in this system, drug effects are independent of γ‐secretase. Expand
The protective effect of Rho-associated kinase inhibitor on aluminum-induced neurotoxicity in rat cortical neurons.
Results reveal that the activation of the Rho-ROCK signaling pathway was involved in Al-induced effects in terms of the cell viability, the production of sAPPalpha, and the formation of amyloid fibril, which provides a novel mechanism underlying Al- induced neurotoxicity. Expand
Ibuprofen Suppresses Interleukin-1β Induction of Pro-Amyloidogenic α1-Antichymotrypsin to Ameliorate β-Amyloid (Aβ) Pathology in Alzheimer's Models
Evidence is presented supporting the hypothesis that ibuprofen-dependent amyloid reduction is mediated by inhibition of an alternate pathway (IL-1β and its downstream target ACT) and not by altered Aβ42 production. Expand
Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease
Studies in both transgenic and non-transgenic animal models of AD have indicated that γ-secretase inhibitors, administered by the oral route, are able to lower brain Aβ concentrations, but scanty data are available on the effects of these compounds on brain A β deposition after prolonged administration. Expand
Diverse compounds mimic Alzheimer disease–causing mutations by augmenting Aβ42 production
Fenofibrate, an antilipidemic agent, and celecoxib, a COX-2–selective NSAID, are among a number of compounds identified that raise Aβ42, raising the possibility that exogenous compounds or naturally occurring isoprenoids might increase A β42 production in humans. Expand